Understanding Stage 0 Breast Cancer (DCIS): Diagnosis, Risks, and Treatment Options

Stage 0 breast cancer, also called ductal carcinoma in situ (DCIS), refers to abnormal cells that remain confined to the lining of a milk duct. These cells have not broken through the duct wall or spread to nearby tissue.

DCIS is non‑invasive and is sometimes described as “precancer.” Although it does not yet invade, it can progress to invasive disease if left untreated.

How Stage 0 Differs From Invasive Breast Cancer

Invasive cancers (stage I and beyond) have crossed the duct or lobule wall and may involve nearby lymph nodes. For example, stage 1A describes a small tumor confined to breast tissue, while stage 1B indicates a small tumor plus limited lymph‑node involvement. The focus of this article is DCIS only; lobular carcinoma in situ (LCIS) is discussed separately.

Key Statistics (U.S.)

• 2023: an estimated 297,790 new invasive breast‑cancer cases.
• 2024: projected 310,720 new invasive cases.
• Breast cancer accounts for roughly 30 % of all new cancer diagnoses in women each year.
• DCIS represents about 20‑25 % of all new breast‑cancer diagnoses (2018 review).
• Women with a prior DCIS diagnosis are ~10 times more likely to develop invasive cancer than women without DCIS (American Cancer Society).
• A 2020 cohort study of >140,000 women treated for DCIS found a three‑fold increase in breast‑cancer‑specific mortality after diagnosis.

Treatment Options

Mastectomy

A mastectomy removes the entire breast. It is not routinely required for DCIS, but may be considered for extensive disease, strong genetic risk, or patient preference.

Lumpectomy (Breast‑Conserving Surgery)

Lumpectomy excises the DCIS lesion together with a small margin of healthy tissue, preserving most of the breast. When followed by radiation, survival outcomes are comparable to mastectomy.

Radiation Therapy

After lumpectomy, radiation uses high‑energy beams to eliminate residual atypical cells. Most women do not need radiation after mastectomy for DCIS (ACS). Treatment is typically delivered five days a week for several weeks.

Hormone (Endocrine) Therapy

If the DCIS is hormone‑receptor‑positive, a five‑year course of tamoxifen or an aromatase inhibitor (e.g., exemestane, anastrozole) can lower the risk of a new DCIS or an invasive cancer in either breast. Long‑term endocrine therapy has been linked to improved overall survival for breast‑cancer patients.

Chemotherapy

Because DCIS is non‑invasive, systemic chemotherapy is generally not indicated.

Risk Factors & Prevention

While the exact cause of DCIS is unknown, certain factors increase risk:

• Increasing age
• Personal history of atypical hyperplasia or other benign breast disease
• Family history of breast cancer or pathogenic BRCA1/BRCA2 mutations
• First childbirth after age 30 or never having been pregnant
• Early menarche (before age 12) or late menopause (after age 55)

Modifiable lifestyle choices—maintaining a healthy weight, limiting alcohol, and staying physically active—can help reduce risk.

Diagnosis Process

Any new lump or change should prompt a clinical evaluation. Imaging (mammography or ultrasound) may reveal a suspicious area, which is then sampled with a needle biopsy. A pathologist examines the tissue under a microscope and reports whether atypical cells are present and how aggressive they appear.

Emotional Support & Resources

Receiving a DCIS diagnosis can be overwhelming. Discuss the findings and treatment options thoroughly with your oncologist, and consider obtaining a second opinion. If anxiety or stress becomes significant, ask your doctor for referrals to counseling or support programs.

The American Cancer Society offers a comprehensive Support Programs and Services page, live chat, and a U.S. helpline at 1‑800‑227‑2345.

Follow‑Up & Surveillance

Because DCIS can evolve into invasive cancer, regular surveillance is essential. Women with a history of DCIS often undergo more frequent mammograms and may benefit from additional imaging modalities as recommended by their care team.

In summary, Stage 0 breast cancer is a treatable, non‑invasive condition that warrants timely diagnosis and personalized management. Treatment options range from breast‑conserving surgery with radiation to mastectomy, with hormone therapy added for hormone‑receptor‑positive disease. Ongoing follow‑up and support services are key to optimal outcomes.